Ranitidine bismuth citrate
Based on 4 publication(s) in Google Scholar
Ranitidine bismuth citrate is a potent, selective and orally active histamine H2-receptor antagonist that inhibits gastric secretion. Ranitidine bismuth citrate antagonizes Histamine (HY-B1204)-induced increases of the guinea-pig isolated rat atrium and Histamine-induced relaxations of the rat isolated uterine horn, with pA2 values of 7.2 and 6.95, respectively. Ranitidine bismuth citrate has selectivity for SARS-CoV-2-infected cells. Ranitidine bismuth citrate also has anti-Helicobacter pylori infection. Ranitidine bismuth citrate inhibits breast tumor development and spread in mice.
For research use only. We do not sell to patients.
- CAS No.: 128345-62-0
- Formula: C19H27BiN4O10S
- Molecular Weight:712.48
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Ranitidine bismuth citrate
MoreAll Histamine Receptor Isoforms
More
Biological Activity
|
H2 Receptor |
Ranitidine bismuth citrate (0.1-1 μM, 5 min) is a potent irreversible inhibitor of both the ATPase (IC50 = 0.69 μM, Ki = 0.97 μM ) and DNA-unwinding (IC50 = 0.74 μM, Ki = 0.39 μM) of the SARS-CoV-2 helicase[2].
Ranitidine bismuth citrate (24 hours) shows potent activity against SARS-CoV-2 with an EC50 value of 2.3 μM in Vero E6 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Monkey kidney Vero E6 cells, human colorectal Caco-2 cells
-
Concentration:400-3,740 μM
-
Incubation Time:48 hours
-
Result:Showed low cytotoxicity with the 50% cytotoxicity concentrations (CC50) ranging from 2.2 mM and 2.5 mM.
Ranitidine bismuth citrate (150 mg/kg; i.p.; once daily; 4 days) suppresses SARS-CoV-2 replication, and relieves virus-associated pneumonia in a golden Syrian hamster model[2].
In the rat, Ranitidine bismuth citrate (3-30 mg/kg p.o.) prevents gastric mucosal damage induced by ethanol (fundic damage) and indomethacin (antral damage)[3].
In ferrets naturally colonized with H. mustelae, Ranitidine bismuth citrate (po; 12-24 mg/kg; twice daily; for 4 weeks) causes a dose related clearance of H. mustelae[3].
Ranitidine (8 mg/kg; oral administration; administered every other day; treatment for 8 days) bismuth citrate reduces the number of CD11b+Ly6Chi cells in the spleen and bone marrow of BALB/c mice[4].
Ranitidine (8 mg/kg; oral administration; administered every other day; treatment for 8 days) bismuth citrate inhibits lung metastasis in BALB/c mice bearing 4T1 breast cancer[4].
Ranitidine (8 mg/kg; oral administration; administered every other day; for 14 days) bismuth citrate inhibits primary tumor growth in the E0771 breast cancer model of C57BL/6 mice[4].
Ranitidine (dose enabling mice to ingest 6-8 mg/kg per day; added to drinking water; changed every 3 days; treatment starting from weaning (~4 weeks) until the end of the experiment (23-26 weeks))bismuth citrate increases the latency of breast tumorigenesis and reduces the number of tumors in LKB1-/-NIC mice[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female Wistar rats (100 to 120 g) were anaesthetized with sodium pentobarbitone (50 mg/kg i.p.), and intravenous with Histamine (100 μg/kg/min) or Pentagastrin (1 μg/kg/min)[1].
-
Dosage:0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 0.6 mg/kg, 1 mg/kg, 3 mg/kg
-
Administration:i.v.; once
-
Result:Inhibited Histamine- and Pentagastrin-induced gastric acid secretion in the perfused stomach preparation of the anaesthetized rat.
-
Animal Model:Male and female Syrian hamsters (6-10 weeks)[2]
-
Dosage:150 mg/kg
-
Administration:Intraperitoneally given; once daily; 4 days
-
Result:Suppressed SARS-CoV-2 replication, and relieved virus-associated pneumonia in a golden Syrian hamster model.
-
Animal Model:BALB/c female mice (5-6-8 week old), orthotopic breast cancer model by injecting 100,000 4T1 cells subcutaneously into the mammary fat pad near the fourth nipple[4].
-
Dosage:8 mg/kg
-
Administration:Oral administration, every other day, 8 days
-
Result:Decreased the proportion of CD11b+Ly6Chi monocytic cells in the spleen and inhibited lung metastasis.
-
Animal Model:C57BL/6 female mice (6-8 week old), orthotopic breast cancer model by injecting 200,000 E0771 cells in 100 μL of Matrigel subcutaneously into the mammary fat pad near the fourth nipple[4].
-
Dosage:8 mg/kg
-
Administration:Oral administration, every other day, 8 days
-
Result:Decreased primary tumor growth starting from approximately day 13 post-tumor cell injection.
-
Animal Model:LKB1-/-/NIC female mice (weaned at about 4 weeks old), spontaneous tumor development model starting from weaning[4].
-
Dosage:6-8 mg/kg
-
Administration:Oral administration, every 3 days, from weaning until the end of the experiment
-
Result:Increased the latency of tumorigenesis by an additional 24 days and reduced the average number of tumors per mouse.
Chemical Information
-
CAS No. 128345-62-0
-
Molecular Weight 712.48
-
Formula C19H27BiN4O10S
-
SMILES
O=[N+](/C=C(NC)/NCCSCC1=CC=C(CN(C)C)O1)[O-].O=C(CC(C([O-])=O)(O)CC([O-])=O)[O-].[Bi+3]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Cell Host Microbe
Immunometabolic reprogramming of macrophages by gut microbiota-derived cadaverine controls colon inflammation. [Abstract]2025 Sep 30:S1931-3128(25)00375-0. PMID: 41033313 -
Brain Sci
Paraventricular Mast Cell-Derived Histamine Activates CRH Neurons to Mediate Adult Visceral Hypersensitivity Induced by Neonatal Maternal Separation. [Abstract]2023 Nov 16;13(11):1595. PMID: 38002554 -
Indian J Ophthalmol
Ranitidine protects Müller cells against ferroptosis in diabetic retinopathy by regulating the AKT1/GSK3β pathway. [Abstract]2026 Feb 1;74(2):250-258. PMID: 41581041 -
Purity & Documentation
References
[1]. Daly MJ, et al. Some in vitro and in vivo actions of the new histamine H2-receptor antagonist, ranitidine. Br J Pharmacol. 1981 Jan;72(1):49-54. [Content Brief]
[2]. Yuan S, et al. Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters. Nat Microbiol. 2020 Nov. 5(11):1439-1448. [Content Brief]
[3]. Stables R, et al. Gastric anti-secretory, mucosal protective, anti-pepsin and anti-Helicobacter properties of ranitidine bismuth citrate. Aliment Pharmacol Ther. 1993 Jun. 7(3):237-46. [Content Brief]
[4]. Vila-Leahey A, et al. Ranitidine modifies myeloid cell populations and inhibits breast tumor development and spread in mice. Oncoimmunology. 2016 Mar 10;5(7):e1151591. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Ranitidine bismuth citrate Related Classifications
HY-B0693A Related Classifications
Powered by Bioz